SCHEMBL25252578

SCHEMBL25252578

CC(C)(C)OC(=O)N1CCC(OC2CC(Oc3cc(C=O)ccn3)C2)CC1

nearest known ligand 0.52

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 18/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25616846 1.00 GPR119 (0.52) GPR119
SCHEMBL3255941 0.92 GPR119 (0.52) GPR119
SCHEMBL25616841 0.91 GPR119 (0.51) GPR119
SCHEMBL25206943 0.91 GPR119 (0.51) GPR119
SCHEMBL21456063 0.86 GPR119 (0.53) GPR119
SCHEMBL21405347 0.86 GPR119 (0.53) GPR119
SCHEMBL23205355 0.86 GPR119 (0.53) GPR119
SCHEMBL25209442 0.86 EPHX2 (0.38) GPR119
SCHEMBL25211911 0.82 GPR119 (0.49) GPR119
SCHEMBL25249923 0.82 GPR119 (0.43) GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250064945-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE GENENTECH, INC. 2025-02-27 US disclosed
EP-4436965-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2024-10-02 EP disclosed
WO-2023096987-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2023-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250064945-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ADRM1, BRAP, VHL GPR119 3040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.